VIATRIS (VTRS, Finance) will pay up to $ 355 million in an annual installment for nine years to solve the opioid claims from the US, local governments and tribal groups. We aim to solve national litigation Despite the fact that Viaatris was described as a minimum in the US opioid market, compared to the company’s historical role in the opioid crisis. The company said that this contract is not wrong or hospitalization.
The annual payment is between $ 27.5 million and $ 40 million, depending on the number of parties participating in the agreement. Viaatris said that the estimation cost of the agreement was already reflected in the annual report of the year, which ended on December 31, 2024.
Pharmaceuticals, headquartered in Pittsburgh, said it continues to develop and supply products that solve public health problems related to Opioid. This includes the general version of the BUPRENORPHINE/Naloxone, a general injectable version of the nail hand and opioid addiction treated to reverse the overdose.
Viaatris also said he is studying new methods of delivery for Meloxicam, a non -opioid painkiller.
The company said that the agreement could focus on fulfilling a wide range of medical missions to expand its portfolio and reach about 1 billion patients every year in various treatment areas.
This article first appeared Guru Focus.
